Motif Bio REVIVE-2 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Antimicrobial Agents and Chemotherapy


You May Also Like

Ascendis Pharma A/S Announces Upcoming Investor Presentations

COPENHAGEN, Denmark, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a ...

Intuitive Surgical Reports New Employee Option Grants for November 2015

SUNNYVALE, Calif., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG) today reported ...